QUICKLINKS AND VIEW OPITONS
European drug agency notes Acomplia less effective in practice than the studies suggested
Posted by .(JavaScript must be enabled to view this email address)
Thursday, October 23, 2008 9:52 am Email this article
[The European Medicines Agency’s (EMEA’s) Committee for Medicinal Products for Human Use (CHMP)] noted, that the effectiveness of Acomplia in clinical practice is more limited than was expected on the basis of the clinical trials, because available data indicate that patients generally take Acomplia only for a short period,” according to a press release from the European Medicines Agency which recommended sales of Acomplia be suspended in Europe.
European medicines agency. The european medicines agency recommends suspension of the marketing authorisation of acomplia [press release]. 2008 Oct 23, http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf.
AUTHOR’S CONTACT INFORMATION
European Medicines Agency
7 Westferry Circus
Canary Wharf
London, E14 4HB, UK
Tel. (44-20) 74 18 84 00
Fax (44-20) 74 18 84 09
.(JavaScript must be enabled to view this email address)
http://www.emea.europa.eu
Articles on the same subject can be found here:
COMMENTS
Please feel free to share your comments about this article.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.